Year All2026202520242023202220212020201920182017 June 30, 2026 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules Read more June 30, 2026 ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel Read more June 1, 2026 ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York Read more May 8, 2026 ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update Read more May 7, 2026 ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression Read more April 30, 2026 ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 Read more April 17, 2026 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules Read more April 13, 2026 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer Read more February 27, 2026 ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read more February 19, 2026 ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 Read more